JP7805969B2 - 強迫性障害を治療するための組成物及び方法 - Google Patents

強迫性障害を治療するための組成物及び方法

Info

Publication number
JP7805969B2
JP7805969B2 JP2022578616A JP2022578616A JP7805969B2 JP 7805969 B2 JP7805969 B2 JP 7805969B2 JP 2022578616 A JP2022578616 A JP 2022578616A JP 2022578616 A JP2022578616 A JP 2022578616A JP 7805969 B2 JP7805969 B2 JP 7805969B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weeks
week
patient
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531919A5 (https=
JP2023531919A (ja
Inventor
コリック，ウラジーミル
バーマン，ロバート
アギアール，ローレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2023531919A publication Critical patent/JP2023531919A/ja
Publication of JP2023531919A5 publication Critical patent/JP2023531919A5/ja
Application granted granted Critical
Publication of JP7805969B2 publication Critical patent/JP7805969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022578616A 2020-06-24 2021-06-24 強迫性障害を治療するための組成物及び方法 Active JP7805969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
US63/043,681 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (3)

Publication Number Publication Date
JP2023531919A JP2023531919A (ja) 2023-07-26
JP2023531919A5 JP2023531919A5 (https=) 2024-06-28
JP7805969B2 true JP7805969B2 (ja) 2026-01-26

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578616A Active JP7805969B2 (ja) 2020-06-24 2021-06-24 強迫性障害を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20230181541A1 (https=)
EP (1) EP4171554A4 (https=)
JP (1) JP7805969B2 (https=)
KR (1) KR20230027189A (https=)
CN (1) CN115968312A (https=)
AU (1) AU2021297249A1 (https=)
BR (1) BR112022025901A2 (https=)
CA (1) CA3187323A1 (https=)
IL (1) IL299301A (https=)
MX (1) MX2022016174A (https=)
PH (1) PH12022553441A1 (https=)
WO (1) WO2021262914A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508525A (ja) 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
JP2021534160A (ja) 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
TW202000205A (zh) * 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021000515A (es) * 2018-07-22 2021-06-08 Biohaven Therapeutics Ltd Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508525A (ja) 2015-03-03 2018-03-29 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
JP2021534160A (ja) 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J．N. DE BOER et al.，"Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis"，Psychiatry Research，2019年08月，Vol. 278，p.294-302，DOI: 10.1016/j.psychres.2019.06.020
Somaye ARABZADEH et al.，"L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study"，Human Psychopharmacology: Clinical and Experimental，2017年05月08日，Vol. 32, No. 4，p.e2584，DOI: 10.1002/hup.258
山田 光彦 他，恐怖記憶の処理過程を制御する新規薬物療法の開発，日本生物学的精神医学会誌，2018年，29巻, 2号，p.60-63

Also Published As

Publication number Publication date
AU2021297249A1 (en) 2023-02-23
BR112022025901A2 (pt) 2023-01-10
WO2021262914A1 (en) 2021-12-30
IL299301A (en) 2023-02-01
EP4171554A1 (en) 2023-05-03
US20230181541A1 (en) 2023-06-15
PH12022553441A1 (en) 2024-03-04
MX2022016174A (es) 2023-01-24
CA3187323A1 (en) 2021-12-30
CN115968312A (zh) 2023-04-14
KR20230027189A (ko) 2023-02-27
JP2023531919A (ja) 2023-07-26
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
Goldstein et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy
US11554117B2 (en) Glutamate agents in the treatment of mental disorders
Weihs et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
Fisher et al. From placebo to panacea
Rush et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
Grant et al. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response
JP2023071832A (ja) フェンフルラミンを用いるドゥーゼ症候群の治療方法
US20250177378A1 (en) Treatment of depression
Reimherr et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
US20140088083A1 (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
CN113710319B (zh) 用于治疗焦虑相关病症的组合物和方法
CA3237768A1 (en) Combination of turso and sodium phenyl butyrate for the treatment of neurodegenerative diseases
by Gabapentin A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin
JP7805969B2 (ja) 強迫性障害を治療するための組成物及び方法
Lindsay et al. Use of modafinil for the treatment of attention deficit/hyperactivity disorder
Dossenbach et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia
JP2013531072A (ja) 統合失調症を処置するための環状アミド誘導体の使用の方法
Aguglia Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long‐term open study
Pae et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial
US20220401391A1 (en) Methods and compositions for treating pain
JP2019514978A (ja) イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療
Nazari et al. Unusual route of buprenorphine administration: an alternative approach for bypassing adverse drug reactions
Warnock et al. Obsessive-compulsive disorders in dermatology patients
Mak The diagnosis and management of obsessive compulsive disorders in primary care
Frye et al. Antiepileptics in the Treatment of Alcohol Withdrawal and Alcohol Use Relapse Prevention

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7805969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150